Last Updated: June 24, 2026

Suppliers and packagers for exxua


✉ Email this page to a colleague

« Back to Dashboard


exxua

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Fabre Kramer EXXUA gepirone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021164 NDA Aytu Therapeutics, LLC 23594-150-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (23594-150-30) 2025-10-01
Fabre Kramer EXXUA gepirone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021164 NDA Aytu Therapeutics, LLC 23594-150-32 32 TABLET, EXTENDED RELEASE in 1 BOTTLE (23594-150-32) 2025-10-01
Fabre Kramer EXXUA gepirone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021164 NDA Aytu Therapeutics, LLC 23594-151-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (23594-151-30) 2025-10-01
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for exxua

Last updated: June 24, 2026

EXXUA suppliers: Who manufactures and supplies Exxua (FDA, NDA holder, contract manufacturers)

Executive summary: Insufficient public, citable information is available to identify the active ingredient, FDA product label holder, and the specific manufacturer-of-record and contract manufacturing network for EXXUA. Without a verified product identity and sourceable regulatory records, listing “suppliers” would risk inaccuracy.

What company makes EXXUA and who are the suppliers

Featured snippet (direct answer): No verified manufacturer-of-record or supplier list can be produced from the information provided.

How “supplier” is typically defined for branded drugs

Suppliers can mean different parties in the regulatory and commercial chain:

  • NDA or marketing authorization holder (drug label holder)
  • Manufacturer of record (drug substance and drug product)
  • Contract manufacturing organizations (fill-finish, sterile manufacturing, compression/encapsulation, packaging)
  • Active pharmaceutical ingredient (API) suppliers
  • Logistics and distribution vendors (usually not disclosed on the label)
  • Wholesalers and specialty distributors (varies by market)

What is EXXUA’s FDA status and Orange Book listing

Featured snippet (direct answer): No Orange Book status, listed patents, or FDA review trail can be validated from the information provided.

What Orange Book data would normally identify suppliers

For small-molecule drugs, the Orange Book typically links:

  • NDA/ANDA numbers
  • Dosage forms
  • Applicant/holder names
  • Listed patent families tied to the product

Which manufacturers supply EXXUA drug substance (API)

Featured snippet (direct answer): Not determinable from the information provided.

API supply chain details that must be sourceable

Accurate supplier identification requires at least one citable anchor such as:

  • FDA drug application documents
  • The product label “Manufactured for” or “Distributed by” sections
  • Inspection database results tied to specific plants
  • Trademark and labeling assignments that are explicitly tied to manufacturing sites

Which contract manufacturers fill-finish EXXUA drug product

Featured snippet (direct answer): Not determinable from the information provided.

Fill-finish depends on dosage form and route

Supplier networks differ materially by:

  • Sterile injectable vs non-sterile oral
  • Pre-filled syringe vs vial vs tablet
  • Controlled substances vs non-controlled products
  • Packaging format and device integration

What labeling text identifies EXXUA’s manufacturer of record

Featured snippet (direct answer): Not determinable from the information provided.

Label elements that normally name suppliers

Common label sections that identify parties include:

  • “Manufactured for” (labeler)
  • “Manufactured by” (manufacturer of record)
  • “Distributed by” (US marketing distribution)
  • Address blocks tied to specific sites

What generic or biosimilar competitors threaten EXXUA and how that affects sourcing

Featured snippet (direct answer): Not determinable from the information provided.

Why competitor activity matters for supply-side risk

When generics ramp:

  • Procurement can shift from single-source to multi-source
  • Input pricing for API/excipients becomes a negotiation lever
  • Contract manufacturers may be requalified for multiple SKUs

How to map EXXUA suppliers across jurisdictions

Featured snippet (direct answer): Not determinable from the information provided.

Jurisdictional mapping requires product identity

Supplier networks differ across:

  • US vs EU vs UK
  • Centralized vs national approval pathways
  • Authorized manufacturing sites and batch release locations

Key Takeaways

  • Supplier identification for EXXUA requires a verified product identity (active ingredient, dosage form, and FDA labeler/manufacturer-of-record).
  • No sourceable details are available in the prompt to produce a correct supplier list.
  • Any specific naming of manufacturers, API sources, or contract manufacturers would not be reliable.

FAQs

  1. How can I identify the manufacturer of record from an EXXUA label?
  2. What Orange Book fields usually reveal the drug applicant and listed patents for a branded product like EXXUA?
  3. How do I distinguish API suppliers from drug product manufacturers for a packaged medicine?
  4. What contract manufacturing roles exist in tablet, capsule, and sterile injectable supply chains?
  5. Where do FDA inspection records typically point for manufacturing-site verification?

References

No sources were cited because no citable, product-specific information for “EXXUA” was provided.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.